phase 2 study

phase 2 study

See Phase study.
References in periodicals archive ?
This single-center, open label Phase 2 study will enroll up to 45 newly diagnosed, previously untreated patients.
The investigational pipeline includes: Qnexa(TM), for which a Phase 2 study has been completed for the treatment of obesity; Testosterone MDTS(R), for which a Phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); EvaMist(TM), for which a Phase 3 study has been completed and an NDA submitted for the treatment of menopausal symptoms; and avanafil, for which a Phase 2 study has been completed for the treatment of erectile dysfunction (ED).
Preliminary results from a phase 2 study of Dacogen in elderly patients with acute myeloid leukemia (AML) and a retrospective survival analysis of Dacogen-treated patients with chronic myelomoncytic leukemia (CMML) were among the data presented.
a privately-held oncology drug development company, today announced the completion of enrollment of its Phase 2 study of Xanafide([R])(amonafide malate) for the treatment of patients with secondary acute myeloid leukemia (AML).
Phase 2 study of Proellex(TM) in the treatment of uterine fibroids and a 40 patient European Phase 2 study of Proellex(TM) in the treatment of endometriosis.
Interim results from the ongoing Phase 2 study of 255 IV bisphosphonate-naive breast cancer patients with established bone metastases, evaluating different doses of denosumab administered monthly or every three months, were presented in an oral session this morning.
We are pleased that Point has two posters accepted for presentation--one on our Phase 2 study of talabostat and rituximab in advanced CLL and another on our Phase 2 study of talabostat and cisplatin in Stage IV metastatic melanoma patients.
The second abstract to be presented is entitled, "A Phase 2 Study of Multiple Doses of Intravenous Polyethylene Glycol (PEG)-uricase in Patients with Hyperuricemia and Refractory Gout.
FDA has indicated to the Company that a New Drug Application (NDA) for INKP-102 could be submitted with data from a Phase I, a single Phase 2 and a single Phase 3 study, if the Phase 2 study were supportive and the Phase 3 study convincing.
This proof-of-concept phase 2 study was designed to investigate the activity and tolerability of MNTX in the post-operative setting.
A phase 2 study of intravenous MNTX for relief of post-operative ileus completed enrollment in October, and top-line results are expected in early 2005.
Examples include statements above (i) regarding the potential benefits of extending the duration of action of PGN0052, (ii) anticipating the optimization of the pharmacokinetic properties of PGN0052 through the application of PEG technology, (iii) regarding the potential receipt of milestone and royalty payments, (iv) regarding the potential formation of a joint development and commercialization agreement, (v) contemplating the potential usefulness of PGN0052 in cystic fibrosis and other indications and (vi) predicting the timing of Phase 2 study results.